EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Resistance Patterns of Gram-Negative Bacteria and Surgical Site Infections Across the Middle East: A Systematic Review and Meta-Analysis

Mee Kamal, Mohammad Al-Tamimi, Ayman D. Alsheikh, Imdat Kilbas, Khaled M. Aboshanab, Muhammad Yasir, Mutasim E. Ibrahim, Shnya R. Hamalaw, Suhaib H. Kakamad, Hussein M. Hamasalih, Hawdang A. Sidiq, Shvan L. Ezzat und 2 weitere

Barw Medical Journal · 01.11.2026

DOI: 10.58742/bmj.v4i2.245 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Barw Medical Journal, online erschienen am 01.11.2026. Verfasst von Mee Kamal und 13 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Surgical site infections (SSIs) are a leading healthcare-associated infection, driven by multidrug-resistant Gram-negative bacteria. Regional data from the Middle East remain limited. This meta-analysis aimed to estimate pooled antimicrobial resistance (AMR) profiles of Gram-negative isolates (GNI) recovered from SSIs.

Methods

PubMed/MEDLINE and Google Scholar were searched in January 2026 for studies reporting AMR in SSI GNI. Eligible studies were English-language reports from the Middle East presenting AMR patterns of Gram-negative bacteria recovered from SSIs. Case reports, laboratory and animal studies, conference papers, and abstract-only publications were ineligible. Proportions were pooled using DerSimonian-Laird random-effects models with Freeman-Tukey double-arcsine transformation, heterogeneity assessed by I².

Results

Twenty-three studies from 8 countries were included. GNI comprised 71.9% (95% CI 60.5-82.2) of all culture-positive isolates and, when restricted to SSI-confirmed specimens, 86.4% (95% CI 63.6-99.3). Escherichia coli was most frequent (27.9%), followed by Pseudomonas aeruginosa (25.8%) and Klebsiella pneumoniae (21.3%). Resistance exceeded 65% for ampicillin in E. coli and for ceftriaxone in both E. coli and K. pneumoniae, with resistance to the remaining third-generation cephalosporins (cefotaxime, ceftazidime) ranging from 46.5% to 85.9%.

Conclusion

Gram-negative SSI isolates in the Middle East showed high resistance across many agent classes, with substantial multidrug resistance, carbapenem resistance, and ESBL production. This regional resistance profile reinforces the need for local, SSI-specific surveillance and antimicrobial stewardship.

Introduction

Surgical site infections (SSIs) are among the most frequent and challenging complications following surgical procedures, significantly impacting patient outcomes, hospital costs, and quality of care worldwide. They are the most frequent healthcare-associated infection in low- and middle-income countries (LMICs) [1]. The proportion of SSIs is reported to be up to 27% of healthcare-associated infections in LMICs [2]. The pooled incidence of SSIs in LMICs is reported to be 5.9 per 100 surgical operations and 11.2 per 100 surgical patients, with rates reaching 11.7% after caesarean section [1]. Even though SSIs were historically dominated by Gram-positive organisms, current epidemiological data show the emergence of multidrug-resistant Gram-negative bacteria (MDR-GNB), which is clinically significant in various healthcare settings. The most commonly reported GNBs were Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. [3]. Despite the use of perioperative antibiotics, SSIs continue to burden postoperative patients, a problem attributed to the emergence of antimicrobial resistance (AMR) [4]. Globally, AMR is a dire health threat [4]. It is estimated to be responsible for approximately five million deaths annually [5]. In the United States, a significant number of pathogens contributing to the SSI were reported to be resistant to standard prophylactic antibiotics [6]. The problem of AMR is particularly pronounced in developing countries [7]. To address this threat, the World Health Organization (WHO) prioritizes antibiotic-resistant bacteria to guide research and control strategies. In its 2024 Bacterial Priority Pathogens List, GNB dominate the critical tier [8]. Despite this global attention, robust regional data regarding resistance patterns in SSI from the Middle East remain scarce [6]. Continuous surveillance is therefore needed and requires a systematic approach that accounts for patient-, procedure-, and environment-related risk factors [9]. This systematic review and meta-analysis aimed to estimate the regional pooled antibiotic-resistance profiles of Gram-negative isolates (GNI) recovered from SSI.

Methods

Study Protocol This systematic review and meta-analysis study was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement guidelines. Data Sources and Search Strategy A comprehensive systematic search was conducted in PubMed/MEDLINE and Google Scholar in January 2026 to identify published studies reporting antibiotic resistance patterns of GNI from SSIs in the Middle East. The search strings were as follows. PubMed/MEDLINE: ("Antimicrobial Resistance"[tiab] OR "Antibiotic Resistance"[tiab] OR MDR[tiab] OR "multidrug-resistant"[tiab]) AND ("Surgical Wound Infection"[Mesh] OR "Surgical Site Infection"[ti] OR SSI[ti] OR "Postoperative Wound Infection"[ti]) AND ("Gram-Negative Bacteria"[Mesh] OR Enterobacteriaceae[tiab] OR "Escherichia coli"[tiab] OR "Klebsiella pneumoniae"[tiab] OR "Pseudomonas aeruginosa"[tiab] OR "Acinetobacter baumannii"[tiab]). Google Scholar: allintitle: "Gram negative" OR Enterobacteriaceae OR "Escherichia coli" OR "E coli" OR Klebsiella OR Pseudomonas OR Acinetobacter "Wound Infection" OR "Surgical Wound Infection" OR "Surgical Site Infection". Manual citation searching of all retrieved articles was performed for additional relevant studies. Eligibility Criteria Studies were included if: (1) they were published in English; (2) reported human clinical samples of GNI recovered from SSIs; (3) reported AMR patterns for SSI GNI; (4) were conducted in the Middle East, which for this review was defined as the transcontinental region comprising the Arabian Peninsula, the Levant, Iraq, Iran, Türkiye, and Egypt; and (5) for studies that sampled mixed clinical specimens, SSI-specific isolates and their antimicrobial-susceptibility data could be extracted separately. Studies were excluded if they: (1) had insufficient data on bacterial species identification, antimicrobial susceptibility testing, or confirmation of SSI; (2) were case reports, in vitro or animal studies, or conference papers; (3) were abstract-only publications; or (4) were in non-recommended journals/publishers [10]. Study Selection Process Two reviewers independently screened the titles and abstracts of all studies to identify studies meeting the eligibility criteria. Retrieved eligible articles underwent full-text review by both reviewers. A third reviewer was enlisted to cast the deciding vote and resolve discrepancies by evaluating conflicting data and reaching a consensus. Duplicate records were removed manually. Data-Collection Process Two reviewers independently extracted data using a structured Microsoft Excel spreadsheet. Discrepancies in extracted data were resolved by consulting a third reviewer. Data extracted from eligible studies included: (1) study characteristics (first author, year of publication, country, study design, study period, and sample size); (2) patient characteristics included demographic variables (age, sex), type of surgery, surgical urgency (elective and emergency), surgical wound classification (clean, clean contaminated, contaminated, dirty), and SSI classification (superficial incisional, deep incisional, organ/space); (3) microbiological profile included total clinical sample counts, culture-positive isolate counts, microbial growth patterns (monomicrobial and polymicrobial), the total number of Gram-negative isolates (GNI), and the number of GNI recovered specifically from SSIs (SSI-specific GNI, i.e., defined by specimen source rather than by species); (4) susceptibility of antimicrobials for SSI-specific GNI across the following antibiotic classes: aminoglycosides (gentamicin, amikacin), carbapenems (imipenem, meropenem), cephalosporins (cefotaxime, ceftazidime, ceftriaxone, cefepime, cefoxitin, cefuroxime), fluoroquinolones (ciprofloxacin, levofloxacin), folate pathway inhibitors (co-trimoxazole), beta-lactam beta-lactamase inhibitors (ampicillin/sulbactam, piperacillin/tazobactam, amoxicillin/clavulanate), penicillins (ampicillin) and monobactams (aztreonam); and (5) antibiotic resistance patterns: MDR, extended-spectrum beta-lactamase (ESBL) and carbapenem resistance (CR). For studies reporting mixed clinical specimens, only data that could be specifically attributed to surgical site infections were extracted for SSI-specific resistance analyses. Outcomes The primary outcome was the AMR profile of GNI recovered from SSIs. For each species, this comprised the pooled proportion of resistance to each individual antimicrobial agent, together with the pooled proportions of isolates classified as MDR, CR, and ESBL-producing. Secondary outcomes were (i) the pooled proportion of GNI among all culture-positive isolates recovered by the included studies (the all-isolate denominator), (ii) the pooled proportion of GNI among isolates confirmed to derive from SSIs (the SSI-restricted denominator), and (iii) the pooled prevalence of each individual species among SSI GNI. These outcomes characterize the organisms that underlie the resistance estimates. Pooled proportions of MDR, CR, and ESBL production were analyzed only when these categories were classified and reported by the primary studies themselves; they were not derived from agent-level resistance percentages. Accordingly, the number of studies and isolates contributing to the MDR, CR, and ESBL estimates may differ from those contributing to agent-level resistance estimates. Quality Assessment Methodological quality was appraised using design-specific Joanna Briggs Institute critical appraisal checklists [11]. Studies were assessed using the checklist corresponding to their design: cross-sectional (8 items), case-control (10 items), cohort (11 items), or case series (10 items). These appraisals informed the risk-of-bias domain of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty assessment. Data Analysis Data were analyzed using the meta package in R version 4.6.0. Proportions were pooled using a DerSimonian-Laird random-effects model with the Freeman-Tukey double-arcsine transformation to stabilize variances and to accommodate studies reporting proportions of 0% or 100%. Each bacterium-antibiotic combination (and likewise each species and resistance-pattern outcome) was pooled only when at least two studies contributed data. Between-study heterogeneity was assessed using Cochran’s Q test and quantified using the I² statistic and the between-study variance (τ²). Each species-level prevalence was pooled independently across its own set of contributing studies; the resulting estimates are therefore not mutually exclusive partitions of a common denominator and are not expected to sum to 100%. To explore geographical variation, resistance was further analyzed in subgroups by country. A formal between-country comparison (Cochran’s Q test between subgroups) was performed only when at least two countries each contributed at least two studies, and the corresponding p-value is reported for these analyses. Temporal trends were explored using random-effects meta-regression of the logit-transformed proportion of resistance on publication year for each bacterium-antibiotic combination. As sampling periods were inconsistently reported, publication year served as a proxy for collection year. These regressions are reported as the odds ratio for resistance per year with 95% confidence intervals, and were carried out only for combinations with at least six studies; significant trends (p < 0.05) were confirmed by leave-one-out analysis and considered robust only if significance persisted after removal of any single study. Certainty of Evidence The certainty of evidence for each pooled estimate was rated with the GRADE approach adapted for prevalence data [12]. As all included studies were observational, every outcome began at low certainty and was rated down for risk of bias, inconsistency, indirectness, imprecision, and publication bias. Inconsistency was judged from the I² statistic, imprecision from the width of the pooled confidence interval and the number of contributing isolates, and risk of bias from the JBI appraisal; publication bias could not be formally assessed.

Results

Study Selection A total of 543 records were identified through electronic searches (PubMed/MEDLINE and Google Scholar) and backward citation searching. After 20 duplicates were removed, 523 records underwent title and abstract screening, of which 422 were excluded. The remaining 101 reports were sought for retrieval; 3 could not be retrieved. The 98 reports assessed for eligibility underwent full-text screening, after which 75 were excluded, leaving 23 included studies (Figure 1) [6,9,13–33]. Study and Patient Characteristics The included studies were published between 2005 and 2026. They were conducted across 8 countries, most frequently Egypt (n = 6), Iraq (n = 4), Türkiye (n = 4), Iran (n = 3), and Saudi Arabia (n = 3). Most included studies were cross-sectional in design (n = 17), followed by prospective cohort studies (n = 3), case-control studies (n = 2), and one case series. Study duration varied and ranged from 4 to 120 months. The combined sample comprised 5,413 patients. Sex distribution was reported for 3,694 patients, with 1,866 males (50.51%) and 1,828 females (49.49%). Patient age was reported with a pooled weighted mean of 44.57 (SD 20.32). Seventeen studies (n = 4,027; 74.39%) sampled SSIs exclusively, while six (n = 1,386; 25.61%) included mixed clinical specimens (Table 1 & Table 2). Methodological quality, assessed using the Joanna Briggs Institute critical appraisal checklist, was generally good across the four designs (Table S1). Table 1. Characteristics of the included studies. Author(s) Ref Year Country Study Design Duration (months) Age (Mean ± SD) Sample size Male Female Hospital stays (d) Infection type JBI Kawtharani et al. [25] 2026 Lebanon Cross-sectional 9 57.0 ± 21 63 23 40 N/A SSI 8/8 Ramadan et al. [13] 2025 Egypt Cross-sectional 6 42.0 ± 14.2 130 76 54 N/A SSI 6/8 Anwar et al. [17] 2025 Iraq Cross-sectional 12 50.1 ± 20.7 128 67 61 4 Mixed Clinical 5/8 Muhammed et al. [23] 2024 Iraq Cross-sectional 6 41.7 ± 18.8 61 31 30 N/A SSI 7/8 Alruways et al. [22] 2023 Saudi Arabia Cross-sectional 12 N/A 31 21 10 N/A Mixed Clinical 6/8 Heidari et al. [14] 2022 Iran Cross-sectional 6 N/A 115 63 52 N/A Mixed Clinical 8/8 Elnagar [16] 2021 Egypt Cross-sectional 12 49.2 ± 13 186 117 69 6.7 SSI 7/8 Ali and Al-Jaff [28] 2021 Iraq Cross-sectional 12 N/A 133** 49 64 N/A SSI 7/8 Hemmati et al. [33] 2020 Iran Cross-sectional 24 49.0 ± 19.6 78 54 24 16.6 SSI 5/8 El-Saed et al. [6] 2020 Saudi Arabia Cross-sectional 120 49.5 ± 18 403* 120 280 N/A SSI 6/8 Raouf et al. [30] 2020 Egypt Prospective Cohort 24 40.9 ± 13.1 57 27 30 12.6 SSI 5/11 Metwally and Aamir [26] 2020 Egypt Cross-sectional 10 42.0 ± 13 135 84 51 7.7 SSI 7/8 Abdulqader and Saadi [31] 2019 Iraq Prospective Cohort 6 45.8 ± 15.2 31 20 11 1.87 SSI 8/11 El-Kholy et al. [18] 2018 Egypt Case-control 12 51.0 ± 21.7 33 24 9 13 SSI 9/10 Al-Awaysheh [9] 2018 Jordan Cross-sectional 12 55.1 ± 10 102 47 55 N/A SSI 7/8 Nasiri et al. [19] 2018 Iran Cross-sectional N/A 43.0 ± 22.1 369 164 205 19.9 Mixed Clinical 7/8 Helal et al. [32] 2015 Egypt Cross-sectional N/A N/A 100 N/A N/A ≥7.0 SSI 7/8 Namıduru et al. [24] 2013 Türkiye Prospective Cohort 4 40.6 ± 22.4 1,397 706 691 17.9 SSI 3/11 Khan et al. [20] 2012 Qatar Case series 24 44.0 ± 14.7 6 5 1 N/A SSI 10/10 Khairy et al. [29] 2011 Saudi Arabia Cross-sectional 9 45.4 ± 12.7 131 93 38 N/A SSI 8/8 Bayram and Balci [21] 2006 Türkiye Cross-sectional 12 N/A 615 N/A N/A N/A Mixed Clinical 6/8 Akıncı et al. [27] 2005 Türkiye Case-control 9 53.1 ± 20.8 128 75 53 19.5 Mixed Clinical 9/10 Surucuoglu et al. [15] 2005 Türkiye Cross-sectional 60 N/A 981 N/A N/A N/A SSI 7/8 *Sex reported for 400 patients. **Sex reported for 113 patients. Abbreviations: N/A, not reported. JBI, Joanna Briggs Institute critical appraisal score. Table 2. Summary of patient characteristics and Gram-negative isolate distribution. Variable Total no. (%) Patients 5,413 (100.00%) Mean Age 44.57 a Male 1,866 (50.51%) b Female 1,828 (49.49%) b Isolate Source 5,413 (100.00%) SSI 4,027 (74.39%) Mixed Clinical 1,386 (25.61%) Surgical Wound Classification 2,523 (100.00%) c Clean-contaminated 1,602 (63.50%) Clean 490 (19.42%) Contaminated 331 (13.12%) Dirty 100 (3.96%) SSI Classification 998 (100.00%) c Superficial incisional 613 (61.42%) Deep incisional 330 (33.07%) Organ-Space 55 (5.51%) Surgical Urgency 698 (100.00%) c Emergency Surgery 411 (58.88%) Elective Surgery 287 (41.12%) Types Of Surgery 2,130 (100.00%) c General/Gastrointestinal Surgery 774 (36.34%) Orthopedic 445 (20.89%) Obstetrics/Gynecology 271 (12.72%) Cardiovascular & Thoracic 225 (10.56%) Pediatric surgery 65 (3.05%) Neurosurgery 39 (1.83%) Plastic surgery 35 (1.64%) Urological surgery 12 (0.56%) Other/unspecified 264 (12.39%) Microbial Growth Pattern 312 (100.00%) c Monomicrobial 188 (60.26%) Polymicrobial 124 (39.74%) Susceptibility Test Method 23 (100.00%) Disc Diffusion 19 (82.61%) Automated systems (VITEK) 2 (8.70%) Mixed methods 2 (8.70%) Microbial Profile among GNB Isolates 2,122 (100.00%) c Pseudomonas aeruginosa 637 (30.02%) Escherichia coli 480 (22.62%) Klebsiella pneumoniae 375 (17.67%) Acinetobacter baumannii 269 (12.68%) Enterobacter species 161 (7.59%) Proteus mirabilis 109 (5.14%) Citrobacter species 25 (1.18%) Other gram negatives** 66 (3.11%) SSI Gram-Negative Bacteria Isolates 1,322 (62.30%) Non-SSI Gram-Negative Bacteria Isolates 800 (37.70%) Microbial Profile among SSI GNB Isolates 1,322 (100.00%) c d Escherichia coli 332 (25.11%) Pseudomonas aeruginosa 320 (24.21%) Klebsiella pneumoniae 280 (21.18%) Acinetobacter baumannii 113 (8.55%) Enterobacter species 99 (7.49%) Proteus mirabilis 90 (6.81%) Citrobacter species 23 (1.74%) Other gram negatives** 65 (4.92%) *Percentages may not add up to 100 due to rounding. **Other GNB isolates include Stenotrophomonas maltophilia: Serratia spp.: Providencia spp.: Salmonella Typhimurium: Burkholderia cepacia: Morganella morganii: Bacteroides fragilis: Proteus vulgaris. a: Number reported is pooled weighted mean across 17 studies. b: Sex distribution was reported in 20 studies (n = 3,694). c: Totals for each section correspond to the number of relevant cases and isolates. d: This total is a crude count of all Gram-negative isolates. Species prevalences are pooled estimates drawn only from studies reporting each species, so their denominators are study-dependent and lower than this total. Abbreviations: SSI, Surgical site infection; GNB, Gram-negative bacteria. Surgical Wound and Procedure Characteristics The majority of surgical wounds were clean-contaminated, 1,602 (63.50%), followed by clean, 490 (19.42%), contaminated, 331 (13.12%), and dirty, 100 (3.96%). The three most frequent surgery types were general/gastrointestinal surgery, 774 (36.34%), orthopedic surgery, 445 (20.89%), and obstetrics/gynecology, 271 (12.72%). A large proportion of the SSIs were superficial incisional, 613 (61.42%), followed by deep incisional, 330 (33.07%), and organ-space, 55 (5.51%). Microbial growth patterns were monomicrobial in 188 (60.26%) and polymicrobial in 124 (39.74%). The most common susceptibility test method was disc diffusion, 19 (82.61%) (Table 2). Main Outcomes Antimicrobial Resistance Estimates Cefoxitin demonstrated the peak pooled resistance in E. coli at 82.4% (95% CI 41.5-100.0), with ampicillin-sulbactam recording the next highest at 74.8% (95% CI 48.1-93.9). K. pneumoniae isolates showed the highest resistance to cefoxitin at 88.3% (95% CI 64.7-99.6), closely trailed by cefotaxime at 85.9% (95% CI 65.1-98.1). Among clinically relevant anti-pseudomonal agents, the greatest resistance level for P. aeruginosa was observed against ceftazidime, 59.1% (95% CI 33.7-82.0), followed by gentamicin, 46.7% (95% CI 28.5-65.3). Among clinically relevant agents, A. baumannii showed the highest resistance to cefepime at 84.9% (95% CI 70.2-95.2), followed by ampicillin-sulbactam at 84.2% (95% CI 55.5-99.2). Among the antibiotics tested against P. mirabilis, ciprofloxacin yielded the top resistance rate of 45.8% (95% CI 15.7-77.6), followed by ceftazidime, 44.9% (95% CI 10.4-82.6). Finally, Enterobacter spp. exhibited a top pooled resistance of 52.0% to ceftazidime (95% CI 23.2-80.1) and a subsequent 49.6% to ciprofloxacin (95% CI 21.9-77.3). Resistance to imipenem and meropenem was 13.9% (95% CI 4.3-27.7) and 7.7% (95% CI 1.2-18.8) in E. coli, 22.2% (95% CI 9.8-37.9) and 23.3% (95% CI 9.6-40.8) in K. pneumoniae, and 34.1% (95% CI 16.0-54.9) and 31.7% (95% CI 14.0-52.6) in P. aeruginosa (Table 3). Table 3. Pooled resistance estimates for individual antimicrobial agents among Gram-negative bacterial species isolated from surgical site infections. Antibiotic drug Resistant (n) Sample (n) Pooled resistance (%) * 95% CI I2 (%) P-value** Escherichia coli Amikacin 36 139 25.6 4.1 - 57.3 93.2

Zitieren

APA

Kamal, M., Al-Tamimi, M., Alsheikh, A. D., Kilbas, I., Aboshanab, K. M., Yasir, M., Ibrahim, M. E., Hamalaw, S. R., Kakamad, S. H., Hamasalih, H. M., Sidiq, H. A., Ezzat, S. L., Çağ, Y., & Abdalla, B. A. (2026). Resistance Patterns of Gram-Negative Bacteria and Surgical Site Infections Across the Middle East: A Systematic Review and Meta-Analysis. Barw Medical Journal. https://doi.org/10.58742/bmj.v4i2.245

Vancouver

Kamal M, Al-Tamimi M, Alsheikh AD, Kilbas I, Aboshanab KM, Yasir M, et al. Resistance Patterns of Gram-Negative Bacteria and Surgical Site Infections Across the Middle East: A Systematic Review and Meta-Analysis. Barw Medical Journal. 2026. doi:10.58742/bmj.v4i2.245

BibTeX
@article{Kamal2026,
  author = {Kamal, Mee and Al-Tamimi, Mohammad and Alsheikh, Ayman D. and Kilbas, Imdat and Aboshanab, Khaled M. and Yasir, Muhammad and Ibrahim, Mutasim E. and Hamalaw, Shnya R. and Kakamad, Suhaib H. and Hamasalih, Hussein M. and Sidiq, Hawdang A. and Ezzat, Shvan L. and Çağ, Yasemin and Abdalla, Berun Anwar},
  title = {Resistance Patterns of Gram-Negative Bacteria and Surgical Site Infections Across the Middle East: A Systematic Review and Meta-Analysis},
  journal = {Barw Medical Journal},
  year = {2026},
  doi = {10.58742/bmj.v4i2.245}
}
Kostenlos starten →